Scarica l'app Stockscreener
6.7721
83.74%
-34.83
Precedente Chiudi:
$41.60
Aprire:
$6.2
Volume 24 ore:
4.93M
Relative Volume:
44.56
Capitalizzazione di mercato:
$63.30M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-83.16%
1M Prestazione:
-80.03%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$5.65
$7.01
Intervallo di 1 settimana:
$5.65
$43.65
Portata 52W:
$5.65
$43.65
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
Nome
Tvardi Therapeutics Inc
Settore
Industria
Telefono
(713) 489-8654
Indirizzo
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
Confronta TVRD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
6.75 | 390.10M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.00 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.04 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
551.61 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
808.25 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.09 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-14 | Iniziato | Raymond James | Outperform |
| 2025-07-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-06-12 | Iniziato | Piper Sandler | Overweight |
| 2025-05-21 | Iniziato | Oppenheimer | Outperform |
| 2025-05-15 | Iniziato | BTIG Research | Buy |
| 2024-06-13 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2024-06-13 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-06-13 | Downgrade | Needham | Buy → Hold |
| 2024-06-13 | Downgrade | Stifel | Buy → Hold |
| 2023-03-08 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-11-01 | Ripresa | Canaccord Genuity | Buy |
| 2021-08-03 | Iniziato | JP Morgan | Neutral |
| 2020-04-21 | Reiterato | H.C. Wainwright | Buy |
| 2019-08-12 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-29 | Reiterato | Laidlaw | Buy |
| 2019-02-06 | Ripresa | Jefferies | Buy |
| 2019-01-15 | Iniziato | BofA/Merrill | Neutral |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Iniziato | Jefferies | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2018-06-28 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-12 | Ripresa | H.C. Wainwright | Buy |
| 2018-02-12 | Aggiornamento | Janney | Neutral → Buy |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
Mostra tutto
Tvardi Therapeutics Inc Borsa (TVRD) Ultime notizie
Live market analysis of Tvardi Therapeutics Inc.2025 Risk Factors & Real-Time Stock Entry Alerts - newser.com
Why Did Tvardi Therapeutics Stock Plummet 87% Pre-Market Today? - Asianet Newsable
Why Is Tvardi Therapeutics Stock (TVRD) Down 85% Today? - TipRanks
Does Tvardi Therapeutics Inc. stock trade at a discount to peersJuly 2025 Reactions & Safe Capital Growth Tips - newser.com
Tvardi Therapeutics' Potential Lung Disease Treatment Fails to Meet Goals; Shares Decline Pre-Bell - MarketScreener
Published on: 2025-10-13 07:20:38 - newser.com
Using RSI to spot recovery in Tvardi Therapeutics Inc.2025 Valuation Update & Reliable Momentum Entry Alerts - newser.com
Will Tvardi Therapeutics Inc. benefit from macro trendsJuly 2025 Update & Breakout Confirmation Trade Signals - newser.com
Using AI based signals to follow Tvardi Therapeutics Inc.2025 Year in Review & Real-Time Stock Entry Alerts - newser.com
Tvardi Therapeutics stock plunges after failed IPF trial data - Investing.com
Barclays initiates coverage on Tvardi Therapeutics stock with Overweight rating - Investing.com
Can swing trading help recover from Tvardi Therapeutics Inc. losses2025 Market Overview & AI Enhanced Execution Alerts - newser.com
Using data models to predict Tvardi Therapeutics Inc. stock movement2025 Earnings Surprises & Community Consensus Trade Alerts - newser.com
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) most popular amongst retail investors who own 57% of the shares, institutions hold 26% - Yahoo Finance
Tvardi Therapeutics Inc. stock volume spike explainedJuly 2025 Pullbacks & Weekly Market Pulse Updates - newser.com
Published on: 2025-10-10 08:50:26 - newser.com
Best data tools to analyze Tvardi Therapeutics Inc. stockJuly 2025 Analyst Calls & High Accuracy Swing Entry Alerts - newser.com
Tvardi Therapeutics Inc. stock daily chart insightsJuly 2025 Pullbacks & Weekly Top Gainers Alerts - newser.com
Is Tvardi Therapeutics Inc 69C a good long term investmentStock Rotation Strategies & Get Tomorrow’s Winners Today With AI - earlytimes.in
Published on: 2025-10-06 07:23:43 - newser.com
Order flow analysis tools used on Tvardi Therapeutics Inc.July 2025 Short Interest & Weekly Stock Performance Updates - newser.com
Is it time to cut losses on Tvardi Therapeutics Inc.Trade Exit Summary & Entry Point Confirmation Alerts - newser.com
Will Tvardi Therapeutics Inc. (69C) stock beat value stocks2025 Market Trends & Weekly Watchlist for Hot Stocks - newser.com
Why analysts remain bullish on Tvardi Therapeutics Inc. stockAnalyst Downgrade & Risk Controlled Daily Plans - newser.com
Will Tvardi Therapeutics Inc. price bounce be sustainableBull Run & Entry Point Confirmation Alerts - newser.com
Is Tvardi Therapeutics Inc. stock cheap at current valuationJuly 2025 Trends & Weekly Setup with ROI Potential - newser.com
What dividend safety score for Tvardi Therapeutics Inc. stockEntry Point & Verified Momentum Watchlists - newser.com
What the charts say about Tvardi Therapeutics Inc. today2025 Volume Leaders & Intraday High Probability Setup Alerts - newser.com
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Published on: 2025-09-30 05:12:21 - newser.com
Published on: 2025-09-30 03:36:47 - newser.com
Tvardi Therapeutics Inc Azioni (TVRD) Dati Finanziari
Non sono disponibili dati finanziari per Tvardi Therapeutics Inc (TVRD). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Tvardi Therapeutics Inc Azioni (TVRD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Terrillion Scott | SEC'Y; CHIEF COMPLIANCE & G.C. |
Feb 28 '25 |
Sale |
4.76 |
163 |
776 |
7,190 |
| Posner Christopher | PRESIDENT AND CEO |
Feb 04 '25 |
Sale |
4.72 |
372 |
1,756 |
13,692 |
| Posner Christopher | PRESIDENT AND CEO |
Nov 04 '24 |
Sale |
0.29 |
3,668 |
1,064 |
168,768 |
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):